Salarius Pharmaceuticals Granted Nasdaq Compliance Extension

An update from Salarius Pharmaceuticals ( (SLRX) ) is now available.

On June 11, 2025, Salarius Pharmaceuticals received an extension from the Nasdaq Hearings Panel to regain compliance with specific Nasdaq Listing Rules. The extension requires Salarius to meet certain milestones, including compliance with the Equity Standard by early July 2025 and the Minimum Bid Price Requirement by early August 2025. Previously, Salarius had received notices for non-compliance due to its stock price and stockholders’ equity falling below required thresholds. The company appealed the delisting determination, and a hearing was conducted on June 3, 2025.

Spark’s Take on SLRX Stock

According to Spark, TipRanks’ AI Analyst, SLRX is a Underperform.

Salarius Pharmaceuticals exhibits significant financial instability, characterized by declining revenues and persistent losses, which severely impacts its stock score. Technically, the stock is on a bearish trend, trading below major moving averages, with negative momentum indicators. The valuation is further weakened by a negative P/E ratio and absence of dividend, making it unattractive to value or income investors. Overall, the stock is highly risky and requires cautious consideration.

To see Spark’s full report on SLRX stock, click here.

More about Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing cancer therapies. The company is engaged in creating treatments targeting rare and hard-to-treat cancers, aiming to address unmet medical needs in the oncology sector.

Average Trading Volume: 213,394

Technical Sentiment Signal: Strong Sell

Current Market Cap: $1.4M

For an in-depth examination of SLRX stock, go to TipRanks’ Overview page.